Skip to main content

Mirvetuximab Soravtansine-gynx Approved for FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

The FDA has approved mirvetuximab soravtansine-gynx (Elahere™, ImmunoGen, Inc.) for adult patients with folate receptor α (FRα)–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Patients are required to have received one to three prior systemic treatment regimens and are selected for treatment based on an FDA-approved test. Mirvetuximab soravtansine-gynx previously received accelerated approval for this indication in November 2022.   Why it matte...

Continue reading

Groundbreaking Results of Mirvetuximab Soravtansine for Ovarian Cancer With Kathleen Moore, MD

Oncology Data Advisor® · Groundbreaking Results of Mirvetuximab Soravtansine for Ovarian Cancer With Kathleen Moore, MD Welcome to Oncology Data Advisor, a digital resource for the multidisciplinary cancer team. At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Kathleen Moore, MD, Associate Director of Clinical Research and Professor of Gynecologic Oncology at the Stephenson Cancer Center at the University of Oklahoma, sat down to discuss in detail her present...

Continue reading